Administration of 5-fluorouracil (5-FU)-incorporated EGFR receptor-targeted aptamers attenuates pancreatic cancer development in a pancreatic cancer mouse model (Ptf1a-Cre; lox-stop-lox-KrasG12D/+; Trp53lox/+) [27]. This evidence concerns the gene PTF1A and pancreatic neoplasm.